Alluvi, previously BI 4744, represents a notable breakthrough in obesity treatment. This dual agonist targeting both GLP-1 and GIP targets demonstrates compelling efficacy in clinical studies, potentially outperforming https://alluvi618308.estate-blog.com/profile